Whalesbook
Aisa Kaise Hua? Numbers Check Karo!
Lupin ne fiscal year ko ekdum rock kar diya! March 2026 ko khatam hone wale quarter mein net profit 89% upar jaake ₹1,460 Crore bana hai, jo pichhle saal isi time ₹773 Crore tha. Aur revenue ki baat karein toh yeh 31.9% badh kar ₹7,475 Crore ho gaya hai. Sirf itna hi nahi, EBITDA toh double se bhi zyada ho gaya, ₹1,321 Crore se seedha ₹2,486 Crore! Is wajah se EBITDA margins bhi 23.3% se sidha 33.3% par pahunch gaye hain. Isi performance par company ne apni history ka sabse bada dividend ₹18 per share announce kiya hai.
Margins Kyun Badhe?
Dekho, single quarter mein 10% ka EBITDA margin jump bahut bada deal hai. Iske peeche kaafi reasons hain jaise company ne operations ko aur efficient banaya hai, high-margin wale products par focus kiya hai aur costs ko bhi control mein rakha hai. Complex generics aur specialty products jaise cheezein jisme profit margins zyada hote hain, woh bhi kaafi help kar rahe hain. Yeh performance Indian pharma sector ke average 24-25% margin se kaafi better hai. Stock bhi apne 52-week high ke aas paas trade kar raha hai, jiska market cap lagbhag ₹1.12 trillion aur P/E ratio 23.92 hai.
Aage Kya?
Analysts isko positive dekh rahe hain aur 'Buy' rating de rahe hain. Unka target price bhi current levels se upar jane ka expectation hai. Company complex generics, specialty medicines aur biosimilars par focus kar rahi hai. Achha dividend dena management ka confidence dikhata hai ki future mein bhi profits aate rahenge. Debt kam karna aur cash position strong rakhna bhi long-term ke liye achha sign hai.
Par Risks Bhi Hain!
Haan, par sab kuch itna smooth bhi nahi hai. US market mein price erosion aur regulatory issues abhi bhi problem create kar sakte hain. USFDA ki observations bhi operations ko affect kar sakti hain. Iss exceptional margin growth ka sustainable rehna bhi ek sawaal hai, kahi yeh sirf one-time cost savings ya specific product cycles ki wajah se toh nahi hai? Continuous innovation aur R&D mein investment zaroori hai.